Drug intelligence / Profile preview

alphaprodine

Development stage
Discontinued
Lead developer
Roche
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Alphaprodine is a synthetic opioid analgesic of the piperidine class that is chemically related to meperidine but has a more rapid onset and shorter duration of action. It acts primarily on the central nervous system (CNS) by binding to mu-opioid receptors, leading to analgesia as well as sedation and euphoria. Alphaprodine was first marketed in 1949 for use in labor and delivery, urologic procedures, minor surgical procedures, dental procedures, and as pre-operative medication. Its effects begin within minutes after intravenous administration and last about 1–2 hours. The drug is metabolized in the liver with excretion mainly via urine. Alphaprodine has a high potential for abuse and dependence similar to other opioids; it is classified as a Schedule II controlled substance in the United States[1][2][6][7].

Brand names
NisentilPrisilidine
Other names
alphaprodinprisilideneprisilidin
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on alphaprodine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alphaprodine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call